Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paroxetine-CR augmentation for PTSD
NCT00215163Phase 3Completed
- Sponsor
- Duke University
- Start
- Dec 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing Paroxetine-CR + PE with Placebo + PE (2 arms). Primary endpoints: Short PTSD Rating Interview and Davidson Trauma Scale. Started Dec 2002; status: completed.
02
Drugs
paroxetine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT00215163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00215163.